Eudragit E 12.5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Eudragit E 12.5
• 英文别名: butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate
• 化学式: C21H37NO6
• 分子量: 399.5
• InChiKey: NEDGUIRITORSKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.31
• 重原子数：
  28
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  82.1
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  甲基丙烯酸二甲氨乙酯 、 甲基丙烯酸甲酯 、 甲基丙烯酸丁酯 、 偶氮二异庚腈 在 偶氮二异庚腈 two 、 正己烷 作用下， 以 甲苯 、 正己烷 为溶剂， 反应 4.0h， 以to obtain 43.7 g (yield: 91%) of the desired polymer as white solid的产率得到Eudragit E 12.5
  参考文献：
  名称：

  Process for preparation of light-sensitive composition polymerizable

  摘要：

  一种光敏液体组合物，其中银卤化物乳液的液滴分散在可聚合化合物中，其特点在于溶解了一种聚合物，其主链基本上由部分取代了亲水基团的碳氢链组成，这些亲水基团在其末端基团中含有-OH或带有孤电子对的氮。还公开了其制备方法。

  公开号：

  US04820610A1

文献信息

• HIGHLY ACTIVE DRUG COMBINATION FOR TREATMENT OF HEPATITIS C VIRUS
  申请人：Atea Pharmaceuticals, Inc.

  公开号：US20200179415A1

  公开（公告）日：2020-06-11

  A combination is provided of Compound 1 or a pharmaceutically acceptable salt thereof (such as Compound 1-A) and Compound 2 or a pharmaceutically acceptable salt thereof (such as Compound 2-A) to treat a host infected with hepatitis C, as well as pharmaceutical compositions and dosage forms, including solid dosage forms thereof.

  提供了复合物1或其药用可接受盐（如复合物1-A）与复合物2或其药用可接受盐（如复合物2-A）的组合物，用于治疗感染丙型肝炎的宿主，以及包括固体剂型在内的药物组合物和剂型。
• PHENOBARBITAL SALTS; METHODS OF MAKING; AND METHODS OF USE THEREOF
  申请人：Sun Tong

  公开号：US20100035904A1

  公开（公告）日：2010-02-11

  Disclosed are new phenobarbital salts, methods of preparation, and uses thereof.

  本发明涉及新的苯巴比妥盐、制备方法及其用途。
• Highly active compounds against COVID-19
  申请人：Atea Pharmaceuticals, Inc.

  公开号：US10874687B1

  公开（公告）日：2020-12-29

  The present invention is the use of a small group of purine nucleotide phosphoramidate disclosed herein or a pharmaceutically acceptable salt thereof in an effective amount for the treatment or prevention of the novel 2019 coronavirus disease (COVID-19) in a host, for example a human, in need thereof.

  本发明涉及在宿主，例如人体中，使用本文所披露的少量嘌呤核苷酸磷酰胺酯或其药学上可接受的盐的有效量，用于治疗或预防新型2019冠状病毒疾病（COVID-19）。
• COMBINATION THERAPY REGIMEN FOR TREATMENT OF HCV
  申请人：JANSSEN PHARMACEUTICALS, INC.

  公开号：US20170087174A1

  公开（公告）日：2017-03-30

  A composition, including a fixed dose composition, comprising Compound (I), Compound (II), and Compound (III) for the treatment of hepatitis C, and methods of manufacture thereof.

  一种包括固定剂量组成，包括化合物(I)，化合物(II)和化合物(III)的组合物，用于治疗丙型肝炎，以及其制造方法。
• Process for producing an oral sustained-release preparation of fasudil hydrochloride
  申请人：ASAHI KASEI PHARMA CORPORATION

  公开号：US20040131679A1

  公开（公告）日：2004-07-08

  Disclosed is an oral sustained-release preparation which contains at least one active ingredient selected from the group consisting of fasudil hydrochloride and a hydrate thereof, the preparation comprising at least one sustained-release coated particle comprising a core having a surface and a coating formed on the surface of the core, wherein the core contains the active ingredient and the coating comprises a coating base material and a specific insoluble auxiliary material, and wherein the preparation exhibits, with respect to the active ingredient, a specific dissolution rate, as measured by the dissolution test. By using the oral sustained-release preparation of the present invention, it becomes possible to surely control the release of fasudil hydrochloride from the preparation, so that the effect of the active ingredient is maintained for a long period of time. Therefore, the burden of the patient who has to take the preparation can be decreased and the compliance with respect to the administration of the preparation can be improved. Also disclosed is a method for evaluating an oral sustained-release preparation containing the active ingredient, wherein the evaluation is conducted with respect to the sustained-release ability of the active ingredient.

  本发明公开了一种口服缓释制剂，其含有从羟氯喹硫酸盐和其水合物组成的群中选择的至少一种活性成分，该制剂包括至少一种缓释包被粒子，其包括具有表面的核心和形成在核心表面上的涂层，其中核心含有活性成分，涂层包括涂层基材料和特定的不溶性辅助材料，且该制剂展现出特定的溶解速率，如溶解测试所测量的。通过使用本发明的口服缓释制剂，可以确保控制羟氯喹硫酸盐的释放，从而使活性成分的效果持续较长时间。因此，可以减轻服用制剂的患者的负担，并提高对制剂的管理的遵从性。还公开了一种评估口服缓释制剂的方法，该方法与活性成分的缓释能力有关。